News | Heart Failure | September 29, 2015

American Heart Association Launches National Initiative to Combat Heart Failure

New association report projects nearly 40 percent diagnosis increase, doubling of associated costs within 15 years

American Heart Association, AHA, heart failure, HF, Rise Above Heart Failure initiative, report

September 29, 2015 — A new report from the American Heart Association (AHA) projects that the number of Americans diagnosed with heart failure (HF) will increase nearly 40 percent within 15 years, and the associated costs will nearly double. With these numbers in mind, the AHA announced the launch of the national Rise Above Heart Failure initiative.  

The goals for the initiative are to reduce HF hospitalizations by 10 percent and increase awareness and understanding of the condition by 10 percent by 2020.

HF, also known as congestive heart failure, is a chronic, progressive condition in which the heart is unable to pump enough blood to meet the body's needs. It is one of the most common heart diseases in the United States, with more than 870,000 new cases reported annually and one in nine deaths including HF as a contributing cause. There are ways to manage and treat the condition, yet about half of those with HF die within five years of being diagnosed.

According to the association's 2015 Impact of Heart Failure Report, by 2030 the number of people diagnosed with HF is expected to increase from about 6 million to nearly 8 million. Total medical costs to treat the condition are projected to increase from $14.3 billion in 2015 to $29.2 billion in 2030. Additionally, indirect costs of HF — including work loss, household productivity losses and premature mortality losses — are projected to increase from $8.2 billion in 2015 to $12.3 billion in 2030.

"Heart failure is one of the most misunderstood health issues facing our country today, yet its impact is undeniable," said Nancy Brown, chief executive officer of the American Heart Association. "We've made significant progress in many areas of cardiovascular disease, and now more than ever, it's important to set this target on heart failure and activate together to help all Americans rise above this potentially deadly condition."

Through Rise Above Heart Failure, nationally supported by Novartis Pharmaceuticals Corp., the AHA plans to:

  • Increase awareness of heart failure and its symptoms and treatments;
  • Promote a heart failure dialogue and inspire people living with heart failure and their loved ones to take a more active role in their care;
  • Encourage all people to make small changes that can lead to healthier lifestyles; and
  • Bring together an alliance of influential organizations to collectively support the goal of reducing the impact of heart failure.

"By having clear goals, we can implement strategies and programs that can help change the trajectory of heart failure," said Clyde W. Yancy, M.D., a past president of the American Heart Association and chief of cardiology and Magerstadt Professor at Northwestern University Feinberg School of Medicine in Chicago. "None of us can do this alone, it will take a commitment of individuals and public and private organizations working together to rise above the staggering impact of heart failure."

Yancy moderated a forum of public health leaders meeting at the National Press Club in Washington, D.C., to present the findings of the AHA report and announce the formation of the Rise Above Heart Failure Alliance. The alliance will include key thought leaders in healthcare, patient advocacy, industry and government who will come together to further assess the current burden of HF. The alliance will also develop strategies to address the issue, such as policy changes, healthcare system improvements, and patient awareness and empowerment initiatives.

Panelists at the National Press Club event included:

  • Janet Wright, M.D., executive director, Million Hearts, Centers for Medicare & Medicaid Services;
  • Michele Blair, chief executive officer, Heart Failure Society of America; and
  • Ryan Olohan, national industry director, healthcare, Google

For more information: www.riseabovehf.org

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init